Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last €76.51 EUR
Change Today 0.00 / 0.00%
Volume 0.0
LLY On Other Exchanges
Symbol
Exchange
New York
Mexico
SIX Swiss Ex
As of 8:43 AM 07/27/15 All times are local (Market data is delayed by at least 15 minutes).

eli lilly & co (LLY) Snapshot

Open
€76.51
Previous Close
€76.51
Day High
€76.51
Day Low
€76.51
52 Week High
07/14/15 - €85.00
52 Week Low
11/3/14 - €43.12
Market Cap
84.9B
Average Volume 10 Days
86.0
EPS TTM
--
Shares Outstanding
1.1B
EX-Date
08/12/15
P/E TM
--
Dividend
€1.99
Dividend Yield
2.15%
Current Stock Chart for ELI LILLY & CO (LLY)

eli lilly & co (LLY) Details

Eli Lilly and Company discovers, develops, manufactures, and sells pharmaceutical products worldwide. It operates in two segments, Human Pharmaceutical Products and Animal Health products. The company offers endocrinology products to treat diabetes; osteoporosis in postmenopausal women and men; human growth hormone deficiency and pediatric growth conditions; and testosterone deficiency. It also provides neuroscience products for the treatment of major depressive disorders, diabetic peripheral neuropathic pain, anxiety disorders, fibromyalgia, and chronic musculoskeletal pain; schizophrenia; attention-deficit hyperactivity disorders; depressive, obsessive-compulsive, bulimia nervosa, and panic disorders; and positron emission tomography imaging of beta-amyloid neurotic plaques in adult brains. In addition, the company offers products for the treatment of non-small cell lung, colorectal, head and neck, pancreatic, metastatic breast, ovarian, bladder, and metastatic gastric cancers, as well as malignant pleural mesothelioma; and cardiovascular products for the treatment of erectile dysfunction and benign prostatic hyperplasia, thrombotic cardiovascular events, and cardiac ischemic complications. Further, it provides animal health products, such as cattle feed additives; protein supplements for cows; leanness and performance enhancers for swine, cattle, and poultry; antibiotics to treat respiratory and other diseases in cattle, swine, and poultry; anticoccidial agents for poultry; and chewable tablets that kill fleas and prevent flea infestations, heartworm diseases, roundworm diseases, hookworm diseases, and whipworm diseases, as well as controls intestinal parasite infections in dogs. Additionally, the company offers products to treat chronic manifestations of atopic dermatitis and congestive heart failure in dogs; chronic allergic dermatitis and kidney diseases in cats. Eli Lilly and Company was founded in 1876 and is headquartered in Indianapolis, Indiana.

41,120 Employees
Last Reported Date: 07/23/15
Founded in 1876

eli lilly & co (LLY) Top Compensated Officers

Chairman, Chief Executive Officer and Preside...
Total Annual Compensation: $1.5M
Chief Financial Officer, Executive Vice Presi...
Total Annual Compensation: $1.0M
Executive Vice President of Science & Technol...
Total Annual Compensation: $1.0M
Senior Vice President and President of Lilly ...
Total Annual Compensation: $682.9K
General Counsel and Senior Vice President
Total Annual Compensation: $765.0K
Compensation as of Fiscal Year 2014.

eli lilly & co (LLY) Key Developments

Eli Lilly and Company Announces Expansion of San Diego Biotechnology Center

Eli Lilly and Company announced that it has revealed plans to expand the Lilly Biotechnology Center located in San Diego, Calif. The expansion will effectively double the company's research presence in San Diego as the company seeks to develop new collaborations in one of the world's leading regions for drug research and development. Set to be completed in 2016, the expansion will feature an additional 175,000 square feet of working space and is expected to generate up to 130 potential new job openings, yielding a 140% increase in the center's space and 70% increase in its staff. Importantly, the space will allow for closer collaboration among the company experts in discovery chemistry and research technologies and biotechnology, which will help accelerate the discovery of new medicines within the company's core therapeutic areas, including immunology. The expansion also signifies the company's investment in obtaining additional top scientific talent. Specifically, the company will be recruiting experts in drug discovery in the disciplines of biotechnology, chemistry and immunology and in immunological clinical development.

Eli Lilly and Company Reports Unaudited Earnings Results for the Second Quarter and Six Months Ended June 30, 2015; Revises Earnings Guidance for the Full Year of 2015

Eli Lilly and Company reported unaudited earnings results for the second quarter and six months ended June 30, 2015. For the quarter, the company reported revenue of $4,978.7 million against $4,935.6 million a year ago. Operating income was $803.0 million against $886.6 million a year ago. Income before income taxes was $679.7 million against $940.4 million a year ago. Net income was $600.8 million or $0.56 per diluted share against $733.5 million or $0.68 per diluted share a year ago. Non-GAAP adjusted revenue was $4,978.7 million against $5,211.2 million a year ago. Non-GAAP adjusted net income was $954.8 million or $0.90 per diluted share against $798.1 million or $0.74 per diluted share a year ago. Operating income in the second quarter of 2015 decline of 9% compared with the second quarter of 2014, driven by higher acquired in-process research and development charges and asset impairment, restructuring and other special charges, partially offset by lower operating expenses. The declines in net income and earnings per share were driven by charges related to the repurchase of debt and lower operating income, partially offset by a lower effective tax rate. For the six months, the company reported revenue of $9,623.4 million against $9,618.7 million a year ago. Operating income was $1,328.2 million against $1,721.4 million a year ago. Income before income taxes was $1,297.6 million against $1,831.2 million a year ago. Net income was $1,130.3 million or $1.06 per diluted share against $1,461.4 million or $1.36 per diluted share a year ago. Non-GAAP adjusted revenue was $9,623.4 million against $10,146.1 million a year ago. Non-GAAP adjusted net income was $1,878.5 million or $1.76 per diluted share against $1,595.9 million or $1.48 per diluted share a year ago. The company has revised certain elements of its 2015 financial guidance on a reported basis and on a non-GAAP basis. Full-year 2015 earnings per share are now expected to be in the range of $2.20 to $2.30 on a reported basis. On a non-GAAP basis, full-year 2015 earnings per share are now expected to be in the range of $3.20 to $3.30. The company now anticipates 2015 revenue of between $19.7 billion and $20.0 billion, reflecting solid underlying performance for the first six months of the year, including the launch trajectories of Jardiance, Trulicity and Cyramza. The company still expects that gross margin as a percent of revenue will be approximately 74.5%  on a reported basis. On a non-GAAP basis, gross margin as a percent of revenue is still expected to be approximately 78.0%, reflecting the exclusion of inventory step-up costs associated with the acquisition of Novartis Animal Health as well as amortization of intangibles. The 2015 tax rate is now expected to be approximately 14.5% on a reported basis, primarily due to the tax impact of the net charge related to the repurchase of debt. The non-GAAP tax rate is now expected to be approximately 21.0%.  Both rates assume a full-year 2015 benefit of the R&D tax credit and other tax provisions up for extension. If these items are not extended, the non-GAAP 2015 tax rate would be approximately 1.5% points higher. Capital expenditures are still expected to be approximately $1.3 billion.

Eli Lilly Mulls Acquisitions

Eli Lilly and Company (NYSE:LLY) intends to look at acquisition opportunities. John Lechleiter, Chairman/Chief Executive Officer of the company told Bloomberg: “We're going to do it mainly through organic growth. So we said the Eli Lilly that is emerging from this period of patent expirations has a strong presence in diabetes, a strong presence in oncology. We aim to grow a presence in neurology with our Alzheimer's molecules. Pain is another area that we're interested in. And then the autoimmune space, we filed with the FDA for approval of a new medicine for psoriasis. In all of those areas we feel we have a good organic base. We will make acquisitions if we see an opportunity to enhance our presence in any one of those areas.”

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
LLY:FP €76.51 EUR 0.00

LLY Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Abbott Laboratories $50.69 USD -0.36
AbbVie Inc $69.34 USD +1.26
Amgen Inc $165.54 USD +6.95
Bristol-Myers Squibb Co $64.30 USD -1.68
Medtronic PLC $75.66 USD -0.35
View Industry Companies
 

Industry Analysis

LLY

Industry Average

Valuation LLY Industry Range
Price/Earnings 44.0x
Price/Sales 4.6x
Price/Book 6.0x
Price/Cash Flow 45.7x
TEV/Sales 4.2x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ELI LILLY & CO, please visit www.lilly.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.